JP2021175715A - Ages formation inhibitory composition - Google Patents

Ages formation inhibitory composition Download PDF

Info

Publication number
JP2021175715A
JP2021175715A JP2020081531A JP2020081531A JP2021175715A JP 2021175715 A JP2021175715 A JP 2021175715A JP 2020081531 A JP2020081531 A JP 2020081531A JP 2020081531 A JP2020081531 A JP 2020081531A JP 2021175715 A JP2021175715 A JP 2021175715A
Authority
JP
Japan
Prior art keywords
ages
celery
formation
suppressing
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020081531A
Other languages
Japanese (ja)
Inventor
龍志 河北
Tatsushi Kawakita
憲男 伊藤
Norio Ito
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aderans Co Ltd
Original Assignee
Aderans Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aderans Co Ltd filed Critical Aderans Co Ltd
Priority to JP2020081531A priority Critical patent/JP2021175715A/en
Priority to KR1020210054059A priority patent/KR20210134509A/en
Priority to CN202110474247.7A priority patent/CN113577118B/en
Priority to CN202410658092.6A priority patent/CN118453674A/en
Publication of JP2021175715A publication Critical patent/JP2021175715A/en
Priority to JP2021193220A priority patent/JP7134322B2/en
Pending legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/23Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60Sugars; Derivatives thereof
    • A61K8/602Glycosides, e.g. rutin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9789Magnoliopsida [dicotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00Preparations for care of the hair
    • A61Q5/02Preparations for cleaning the hair
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00Preparations for care of the hair
    • A61Q5/12Preparations containing hair conditioners
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00Preparations for affecting hair growth
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59Mixtures
    • A61K2800/592Mixtures of compounds complementing their respective functions
    • A61K2800/5922At least two compounds being classified in the same subclass of A61K8/18

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

To provide AGEs formation inhibitory compositions having excellent safety and usability.SOLUTION: AGEs formation inhibitory compositions contain, as an active ingredient, celery extract and rutin.SELECTED DRAWING: None

Description

本発明は、AGEs形成抑制用組成物に関し、詳しくは、AGEs形成抑制剤、中でもAGEs形成抑制外用剤に関する。 The present invention relates to a composition for suppressing AGEs formation, and more particularly to an agent for suppressing AGEs formation, particularly an external preparation for suppressing AGEs formation.

AGEs(Advanced Glycation End Products の略語)は、タンパク質の糖化反応により生成される産物の総称であり、最終糖化産物又は後期糖化生成物などと言われる。AGEsは、体内に蓄積し,糖尿病、動脈硬化、神経性疾患など、加齢性慢性疾患等に関わる様々な症状を引き起こす又は症状を悪化させると報告されており、特に老化との関与が指摘されている。 AGEs (abbreviation for Advanced Glycation End Products) is a general term for products produced by the glycation reaction of proteins, and is called advanced glycation end products or late glycation products. It has been reported that AGEs accumulate in the body and cause or exacerbate various symptoms related to age-related chronic diseases such as diabetes, arteriosclerosis, and neurological diseases, and their involvement in aging has been pointed out. ing.

図1は、髪の毛が成長するメカニズムを模式的に示した断面図である。毛の根元にある毛乳頭細胞は、髪の毛を成長させる栄養素や発毛因子を毛母細胞に送り出している。毛母細胞は、毛乳頭細胞のまわりにあり、活発に細胞分裂を行って髪の毛を作っている細胞である。したがって、発毛因子を毛母細胞がしっかりと受けとることで、髪の毛の成長が維持されることになる。逆に、毛乳頭細胞と毛母細胞との協調関係がうまくいかなくなると、薄毛になってしまう。 FIG. 1 is a cross-sectional view schematically showing the mechanism of hair growth. The dermal papilla cells at the base of the hair send nutrients and hair growth factors that grow the hair to the hair matrix cells. Hair matrix cells are cells that surround the dermal papilla cells and actively undergo cell division to make hair. Therefore, the hair growth factor is firmly received by the hair matrix cells, so that the hair growth is maintained. On the contrary, if the cooperative relationship between the dermal papilla cells and the hair matrix cells is not good, the hair becomes thin.

最近のわれわれの研究により(非特許文献1)、毛乳頭細胞の所にAGEsが溜まってくると、2つの細胞の協調関係を狂わす炎症物質が毛乳頭細胞から出てくることがわかってきた。その結果、毛母細胞の細胞分裂が障害され、髪の毛の成長が抑えられてしまう。 Our recent research (Non-Patent Document 1) has revealed that when AGEs accumulate at the dermal papilla cells, inflammatory substances that disrupt the cooperative relationship between the two cells emerge from the dermal papilla cells. As a result, cell division of hair matrix cells is impaired and hair growth is suppressed.

Eur J Dermatol. 2015 Jul-Aug;25(4):359-61Eur J Dermatol. 2015 Jul-Aug; 25 (4): 359-61 Matsui T, Yamagishi S, et al. Immunol Lett. 2015 Oct;167(2):141-6Matsui T, Yamagishi S, et al. Immunol Lett. 2015 Oct; 167 (2): 141-6

かかる場合、全体的に髪の毛が細く、薄くなっていくので、どちらかと言うと女性に多く見られる頭頂部(頭のてっぺん)のびまん性の薄毛にAGEsが関係しているようである。なお、AGEsが毛乳頭細胞に作用するには、細胞に存在する鍵穴にAGEsがはまりこまなければならない。このAGEsがはまりこむ穴は、AGEs受容体と言われ、英語でRAGE(レイジ)と呼ばれている。つまり、AGEsは、しわやたるみだけでなく、薄毛にも関わっていたのである。 In such cases, the hair becomes thinner and thinner as a whole, so it seems that AGEs are related to the diffuse thinning hair on the crown (top of the head), which is more common in women. In addition, in order for AGEs to act on dermal papilla cells, AGEs must fit into the keyway existing in the cells. The hole into which these AGEs fit is called the AGEs receptor, and is called RAGE in English. In other words, AGEs were involved not only in wrinkles and sagging, but also in thinning hair.

本発明は上記問題を解決するものであり、その目的とするところは、安全性及び有用性に優れたAGEs形成抑制用組成物を提供することにある。 The present invention solves the above problems, and an object of the present invention is to provide a composition for suppressing the formation of AGEs, which is excellent in safety and usefulness.

本発明は、有効成分として、セロリエキスとルチンとを含むAGEs形成抑制用組成物を提供する。セロリエキスとルチンを含む組成物を、以下、「CR2」と呼ぶことがある。 The present invention provides a composition for suppressing the formation of AGEs containing celery extract and rutin as active ingredients. The composition containing celery extract and rutin may be hereinafter referred to as "CR2".

ある一形態においては、セロリエキスはセロリの水抽出液である。 In one form, the celery extract is a water extract of celery.

ある一形態においては、セロリの重量と水の体積との比率が1/5〜1/0.2である。 In one form, the ratio of weight of celery to volume of water is 1/5 to 1 / 0.2.

ある一形態においては、セロリはセロリ茎部を含む。 In one form, celery comprises the celery stalk.

また、本発明は、上記いずれかのAGEs形成抑制用組成物を含むAGEs形成抑制剤を提供する。 The present invention also provides an AGEs formation inhibitor containing any of the above compositions for suppressing AGEs formation.

また、本発明は、外用剤である上記AGEs形成抑制剤を提供する。 The present invention also provides the above-mentioned AGEs formation inhibitor, which is an external preparation.

また、本発明は、シャンプー、リンス又は育毛剤である上記AGEs形成抑制剤を提供する。 The present invention also provides the above-mentioned AGEs formation inhibitor, which is a shampoo, conditioner or hair restorer.

本発明によれば、安全性及び有用性に優れたAGEs形成抑制用組成物が提供される。 According to the present invention, a composition for suppressing the formation of AGEs, which is excellent in safety and usefulness, is provided.

髪の毛が成長するメカニズムを模式的に示した断面図である。It is sectional drawing which shows typically the mechanism of hair growth. セロリエキス、ルチン、又は両方を存在させた場合に、アルブミンとグリセルアルデハイドとからのAGEsの生成量がどのように変化するかを示したグラフである。It is a graph which showed how the amount of production of AGEs from albumin and glyceraldehyde is changed in the presence of celery extract, rutin, or both. セロリエキスを存在させた場合に、ヒト内皮細胞のアルブミンによる酸化ストレスレベルがどのように変化するかを示したグラフである。It is a graph which showed how the oxidative stress level by albumin of a human endothelial cell changes in the presence of a celery extract. セロリエキスを存在させた場合に、ヒト内皮細胞のアルブミンによるRAGE遺伝子発現レベルがどのように変化するかを示したグラフである。It is a graph which showed how the RAGE gene expression level by albumin of a human endothelial cell changes in the presence of a celery extract.

<セロリエキス>
「セロリ」は、学名が「Apium graveolens var. dulce」であり、セリ科の植物である。セロリは、淡色野菜に分類され、大別して、中間種、緑色種、黄色種、東洋在来種の4品種が流通している。本発明では、セロリの茎、葉、又は茎及び葉を使用する。セロリエキスは、セロリの茎又は葉から非水溶性成分を取り除いた液体成分をいう。
<Celery extract>
"Celery" has a scientific name of "Apium graveolens var. Dulce" and is a plant of the Umbelliferae family. Celery is categorized as light-colored vegetables, and roughly classified into four varieties: intermediate varieties, green varieties, yellow varieties, and oriental native varieties. In the present invention, celery stems, leaves, or stems and leaves are used. Celery extract refers to a liquid component obtained by removing a water-insoluble component from the stem or leaf of celery.

セロリエキスは、原料であるセロリを準備し、粉砕、搾汁、濾過、固液分離、及び要すれば精製を行うことで製造することができる。搾汁の際に、粉砕したセロリに溶媒を添加してもよい。そのことで、セロリから液体成分を効率良く抽出することができる。 The celery extract can be produced by preparing celery as a raw material and performing crushing, squeezing, filtration, solid-liquid separation, and purification if necessary. A solvent may be added to the crushed celery during squeezing. As a result, the liquid component can be efficiently extracted from celery.

セロリから液体成分を抽出する溶媒としては、水又は1,3-ブチレングリコール、あるいは他の有機溶媒を用いることができる(有機溶媒を含んだ水も含む。)。有機溶媒は、典型的にはメタノールやエタノールが挙げられるが、アセトン、ジエチルエーテル、酢酸エチル、ヘキサンなど、公知の有機溶媒を広く含む。抽出溶媒として水を使用する場合は、得られるセロリエキスのpHを安定させる観点から、好ましくは、リン酸緩衝液を使用する。 As the solvent for extracting the liquid component from celery, water, 1,3-butylene glycol, or another organic solvent can be used (including water containing an organic solvent). Examples of the organic solvent include methanol and ethanol, but a wide range of known organic solvents such as acetone, diethyl ether, ethyl acetate and hexane are included. When water is used as the extraction solvent, a phosphate buffer solution is preferably used from the viewpoint of stabilizing the pH of the obtained celery extract.

例えば、所定量のセロリに所定量の水を加え、セロリをミキサーで粉砕、濾過及び遠心分離を行ったのち、透明な上澄みを採取して、セロリエキスを得ることができる。セロリと水の使用量は、例えば、セロリ粉砕物の重量と水の体積との比率が1/5〜1/0.2になる量である。セロリと水の使用量をこの範囲にすることで、得られるセロリエキスの安定性が向上する。セロリ粉砕物の重量と水の体積との比率は、好ましくは、1/2〜1/0.5、より好ましくは1/1.5〜1/0.7である。 For example, a predetermined amount of water is added to a predetermined amount of celery, the celery is crushed with a mixer, filtered and centrifuged, and then a transparent supernatant is collected to obtain a celery extract. The amount of celery and water used is, for example, an amount in which the ratio of the weight of the celery pulverized product to the volume of water is 1/5 to 1 / 0.2. By keeping the amount of celery and water used in this range, the stability of the obtained celery extract is improved. The ratio of the weight of the celery pulverized product to the volume of water is preferably 1/2 to 1 / 0.5, more preferably 1 / 1.5 to 1 / 0.7.

セロリエキスの原料として、濃縮セロリ汁又は還元セロリ汁を使用してよく、そうすることで、前記セロリの準備、破砕及び搾汁と云った工程を省くことが可能である。医薬部外品として市販されているセロリエキスを使用してもよい。 Concentrated celery juice or reduced celery juice may be used as the raw material for the celery extract, thereby eliminating the steps of preparing, crushing and squeezing the celery. A celery extract commercially available as a quasi-drug may be used.

セロリエキスの使用量は、AGEs形成抑制用組成物の体積を基準にして、0.2〜5.0重量%である。セロリエキスの使用量を上記範囲にすることで、AGEs形成抑制効果が向上する。セロリエキスの使用量は、AGEs形成抑制用組成物の体積を基準にして、好ましくは0.4〜3.0重量%、より好ましくは0.7〜2.0重量%である。 The amount of celery extract used is 0.2 to 5.0% by weight based on the volume of the composition for suppressing AGEs formation. By setting the amount of celery extract used within the above range, the effect of suppressing the formation of AGEs is improved. The amount of the celery extract used is preferably 0.4 to 3.0% by weight, more preferably 0.7 to 2.0% by weight, based on the volume of the composition for suppressing the formation of AGEs.

<ルチン>
ルチンは、高等植物や野菜・果物に広く含まれている無味、無臭のフラボノイド類の一つであり、古くからビタミンCとともに脆弱化した毛細血管を補強・改善する作用、フラボノイド類の持つ着色、酸化防止作用をはじめ、多々の機能を有する天然抽出物として関心がもたれており、医薬品、医薬品原料としての用途において実績のある物質である。
<Rutin>
Rutin is one of the tasteless and odorless flavonoids widely contained in higher plants, vegetables and fruits, and has the effect of reinforcing and improving the fragile capillaries together with vitamin C for a long time. It is of interest as a natural extract with many functions, including antioxidant activity, and is a proven substance for use as pharmaceuticals and raw materials for pharmaceuticals.

ルチンは、例えば、蕎麦の新芽等のルチン高含有植物から抽出することで、製造することができる。ルチンは、例えば、市販されているものを使用することができる。ルチンは、水溶性が増大するよう改変されたルチンであってもよい。かかる水溶性ルチンの具体例としては、αグルコシル化ルチンが挙げられる。 Rutin can be produced, for example, by extracting from a rutin-rich plant such as a sprout of buckwheat. As the rutin, for example, commercially available ones can be used. Rutin may be rutin modified to increase water solubility. Specific examples of such water-soluble rutin include α-glucosylated rutin.

ルチンの使用量は、AGEs形成抑制用組成物の体積を基準にして、20〜500μM(マイクロモル/リットル)である。ルチンの使用量を上記範囲にすることで、AGEs形成抑制効果が向上する。ルチンの使用量は、AGEs形成抑制用組成物の体積を基準にして、好ましくは50〜250μM、より好ましくは80〜150μMである。 The amount of rutin used is 20 to 500 μM (micromol / liter) based on the volume of the composition for suppressing AGEs formation. By setting the amount of rutin used in the above range, the effect of suppressing the formation of AGEs is improved. The amount of rutin used is preferably 50 to 250 μM, more preferably 80 to 150 μM, based on the volume of the composition for suppressing AGEs formation.

<AGEs形成抑制用組成物>
本発明のAGEs形成抑制用組成物は、AGEs形成抑制剤として、優れたAGEs形成抑制効果を示す。本発明のAGEs形成抑制用組成物は、例えば、頭皮においてAGEsの形成を抑えるだけでなく、すでに頭皮や毛乳頭に存在するAGEsによる内皮細胞障害や炎症反応を抑制することで、育毛をサポートする。本発明のAGEs形成抑制用組成物は、石鹸及び化粧品等に含有させて外用剤として使用する場合、特にシャンプー、リンス及び育毛剤等に含有させて外用剤として使用する場合に、極めて有用性が高い。
<Composition for suppressing AGEs formation>
The composition for suppressing AGEs formation of the present invention exhibits an excellent effect of suppressing AGEs formation as an AGEs formation inhibitor. The composition for suppressing AGEs formation of the present invention not only suppresses the formation of AGEs in the scalp, but also supports hair growth by suppressing endothelial cell damage and inflammatory reaction due to AGEs already present in the scalp and dermal papilla. .. The composition for suppressing the formation of AGEs of the present invention is extremely useful when it is contained in soaps and cosmetics and used as an external preparation, especially when it is contained in shampoos, rinses and hair growth agents and used as an external preparation. high.

<CR2(セロリエキス+ルチン)の作用に関して>
医薬部外品であり薬用石鹸、シャンプー・リンス等、除毛剤、育毛剤、その他の薬用化粧品、腋臭防止剤、禁忌剤、浴用剤として認められている二つの成分セロリエキスとルチンを用いて、AGEs形成抑制効果、ならびにAGEsによる酸化ストレス産生とRAGE遺伝子発現抑制作用について検討を行った。まず、新鮮なセロリ50gに50mlのリン酸緩衝液を加え、ミキサーで粉砕後、カーゼで濾過し、遠心分離を行ったのち、透明な上澄みを採取してセロリエキスとして実験に用いた。ルチンは、和光純薬から純度90%のものを購入した。
<Regarding the action of CR2 (celery extract + rutin)>
Using quasi-drugs, medicated soap, shampoo, conditioner, depilatory, hair restorer, other medicated cosmetics, axillary odor inhibitor, contraindicated agent, and two ingredients recognized as bathing agents, celery extract and rutin. , AGEs formation inhibitory effect, and oxidative stress production and RAGE gene expression inhibitory effect by AGEs were investigated. First, 50 ml of phosphate buffer was added to 50 g of fresh celery, pulverized with a mixer, filtered with a case, centrifuged, and then a clear supernatant was collected and used as a celery extract in an experiment. Rutin was purchased from Wako Pure Chemical Industries, Ltd. with a purity of 90%.

1)AGEs形成抑制作用
0.2Mリン酸バッファー(pH7.4)溶液中で25mg/mlのウシ血清アルブミンと2mMのグリセルアルデハイド(還元糖)を最終濃度1%セロリエキス、最終濃度100μMルチン存在、非存在下に1日間37度でインキュベーションした。その後、サンプルをリン酸バッファーで透析後、AGEs化したアルブミン量をAGEsに対するモノクローナル抗体を用いたELISA法で既報のごとく測定した(参考:非特許文献2)。標準曲線におけるAGEs化したアルブミンの50%阻害濃度を1Uとした。
1) AGEs formation inhibitory effect: 25 mg / ml bovine serum albumin and 2 mM glyceral dehide (reducing sugar) in a 0.2 M phosphate buffer (pH 7.4) solution with a final concentration of 1% celery extract and a final concentration of 100 μM rutin. Incubated at 37 ° C for 1 day in the absence of. Then, the sample was dialyzed against a phosphate buffer, and the amount of AGEs-ized albumin was measured by the ELISA method using a monoclonal antibody against AGEs as previously reported (Reference: Non-Patent Document 2). The 50% inhibition concentration of AGEs-ized albumin on the standard curve was defined as 1 U.

結果:ELISA法により、グリセルアルデハイドに由来するAGEsを特異的に測定したところ、ルチン、セロリエキスそれぞれ単独の投与では、AGEsの形成は抑えられる傾向にはあったものの、その効果は統計学的に有意ではなかった。しかし、最終濃度1%セロリエキスと最終濃度100μMルチン共存下では、AGEsの形成が有意に抑えられることが見出された(図2、各群N=5、結果は平均値±標準偏差。統計は、Student t testで解析。*,p<0.05)。 Results: When AGEs derived from glyceraldehyde were specifically measured by the ELISA method, the formation of AGEs tended to be suppressed by the administration of rutin and celery extract alone, but the effect was statistical. Was not significant. However, it was found that the formation of AGEs was significantly suppressed in the coexistence of the final concentration of 1% celery extract and the final concentration of 100 μM rutin (Fig. 2, N = 5 in each group, the result was mean ± standard deviation. Statistics. Was analyzed by the Student t test. *, P <0.05).

2)内皮細胞における酸化ストレス産生とAGEs受容体であるRAGE遺伝子発現誘導に対する作用
ヒト内皮細胞を1%セロリエキス存在、非存在下に100μg/mlのAGEs化したアルブミン(以下、AGEs)あるいは非糖化コントロールアルブミン(以下、アルブミン)で処理し、30分後に酸化ストレス産生を、4時間後にRAGE遺伝子発現をそれぞれ蛍光試薬法とRT-PCR法で解析した。
2) Oxidative stress production in endothelial cells and action on induction of expression of RAGE gene, which is an AGEs receptor After treatment with control albumin (hereinafter referred to as albumin), oxidative stress production was analyzed 30 minutes later, and RAGE gene expression was analyzed 4 hours later by the fluorescent reagent method and the RT-PCR method, respectively.

結果:1%セロリエキスにより、内皮細胞においてAGEsによる酸化ストレス産生とRAGE遺伝子の発現誘導が抑えられることが明らかにされた(図3と図4、酸化ストレスは、各群N=12、RAGE遺伝子発現は、各群N=5、結果は平均値±標準偏差。統計は、Student t testで解析。*,p<0.05,**,p<0.01、アルブミン+2mMグリセルアルデハイド(1日間))。 Results: It was clarified that 1% celery extract suppressed the production of oxidative stress by AGEs and the induction of RAGE gene expression in endothelial cells (Figs. 3 and 4, oxidative stress was N = 12 in each group, RAGE gene). Expression was N = 5 in each group, results were mean ± standard deviation. Statistics were analyzed by Student t test. *, P <0.05, **, p <0.01, albumin + 2 mM glyceraldide (1 day)) ..

<考察>
本研究では、2つの医薬部外品であるセロリエキスとルチンを合わせることで(CR2)、AGEsの形成が有意に抑えられることが世界で初めて明らかにされた。さらに、セロリエキスは、抗酸化、RAGE発現抑制作用を介して、内皮細胞においてAGEsに対する反応性を低下させることが示された。以上のことから、CR2は、頭皮におけるAGEsの形成を抑えるだけでなく、すでに頭皮や毛乳頭に存在するAGEsによる内皮細胞障害や炎症反応を抑制することで、育毛をサポートする可能性が考えられる。AGEs-RAGE系のしわ、しみ、薄毛など美容への悪影響を鑑みると、CR2はシャンプー・リンスや育毛剤として極めて有用性が高い成分の組み合わせだと予想される。
<Discussion>
In this study, it was revealed for the first time in the world that the formation of AGEs was significantly suppressed by combining two quasi-drugs, celery extract and rutin (CR2). Furthermore, it was shown that celery extract reduces the reactivity to AGEs in endothelial cells through antioxidant and RAGE expression inhibitory effects. From the above, it is considered that CR2 not only suppresses the formation of AGEs in the scalp, but also suppresses the endothelial cell damage and inflammatory reaction caused by AGEs already present in the scalp and dermal papilla to support hair growth. .. Considering the adverse effects on beauty such as wrinkles, age spots, and thinning hair of AGEs-RAGE, CR2 is expected to be a combination of ingredients that are extremely useful as shampoo / rinse and hair restorer.

セロリエキスの使用量は、AGEs形成抑制用組成物の重量を基準にして、0.2〜5.0重量%である。セロリエキスの使用量を上記範囲にすることで、AGEs形成抑制効果が向上する。セロリエキスの使用量は、AGEs形成抑制用組成物の体積を基準にして、好ましくは0.4〜3.0重量%、より好ましくは0.7〜2.0重量%である。
The amount of celery extract used is 0.2 to 5.0% by weight based on the weight of the composition for suppressing AGEs formation. By setting the amount of celery extract used within the above range, the effect of suppressing the formation of AGEs is improved. The amount of the celery extract used is preferably 0.4 to 3.0% by weight, more preferably 0.7 to 2.0% by weight, based on the volume of the composition for suppressing AGEs formation.

Claims (7)

有効成分として、セロリエキスとルチンとを含むAGEs形成抑制用組成物。 A composition for suppressing the formation of AGEs containing celery extract and rutin as active ingredients. セロリエキスはセロリの水抽出液である請求項1に記載のAGEs形成抑制用組成物。 The composition for suppressing the formation of AGEs according to claim 1, wherein the celery extract is a water extract of celery. セロリの重量と抽出水の体積との比率が1/5〜1/0.2である請求項1又は2に記載のAGEs形成抑制用組成物。 The composition for suppressing AGEs formation according to claim 1 or 2, wherein the ratio of the weight of celery to the volume of extracted water is 1/5 to 1 / 0.2. セロリはセロリ茎部を含む請求項1〜3のいずれか一項に記載のAGEs形成抑制用組成物。 The composition for suppressing the formation of AGEs according to any one of claims 1 to 3, wherein the celery contains a celery stem. 請求項1〜4のいずれか一項に記載のAGEs形成抑制用組成物を含むAGEs形成抑制剤。 An AGEs formation inhibitor containing the composition for suppressing AGEs formation according to any one of claims 1 to 4. 外用剤である請求項5に記載のAGEs形成抑制剤。 The AGEs formation inhibitor according to claim 5, which is an external preparation. シャンプー、リンス又は育毛剤である請求項5に記載のAGEs形成抑制剤。 The AGEs formation inhibitor according to claim 5, which is a shampoo, conditioner or hair restorer.
JP2020081531A 2020-05-01 2020-05-01 Ages formation inhibitory composition Pending JP2021175715A (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2020081531A JP2021175715A (en) 2020-05-01 2020-05-01 Ages formation inhibitory composition
KR1020210054059A KR20210134509A (en) 2020-05-01 2021-04-27 Composition for inhibiting formation of AGEs
CN202110474247.7A CN113577118B (en) 2020-05-01 2021-04-29 Composition for inhibiting AGEs formation
CN202410658092.6A CN118453674A (en) 2020-05-01 2021-04-29 Composition for inhibiting AGEs formation
JP2021193220A JP7134322B2 (en) 2020-05-01 2021-11-29 Composition for suppressing AGEs formation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2020081531A JP2021175715A (en) 2020-05-01 2020-05-01 Ages formation inhibitory composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021193220A Division JP7134322B2 (en) 2020-05-01 2021-11-29 Composition for suppressing AGEs formation

Publications (1)

Publication Number Publication Date
JP2021175715A true JP2021175715A (en) 2021-11-04

Family

ID=78242985

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020081531A Pending JP2021175715A (en) 2020-05-01 2020-05-01 Ages formation inhibitory composition

Country Status (3)

Country Link
JP (1) JP2021175715A (en)
KR (1) KR20210134509A (en)
CN (2) CN118453674A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023190518A1 (en) * 2022-03-30 2023-10-05 国立研究開発法人産業技術総合研究所 Oxidative stress inhibitor, oxidative stress inhibitory composition, and oxidative stress inhibitory device

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009096731A (en) * 2007-10-15 2009-05-07 Kumamoto Univ Carboxymethyl arginine production inhibitor
JP2016006036A (en) * 2014-05-26 2016-01-14 アークレイ株式会社 AGEs-DEGRADING AGENT AND USE THEREOF
JP2018188375A (en) * 2017-04-28 2018-11-29 株式会社アンチエイジングコミュニケーション Pentosidine production inhibitor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015224202A (en) * 2014-05-26 2015-12-14 学校法人同志社 AGEs DECOMPOSITION ACTIVITY ENHANCER OF OPH
CN104651154B (en) * 2015-02-13 2016-08-03 四川嘉粮窖生态酒业有限公司 A kind of rich in apigenin, the ecological health-care wine and preparation method thereof of rutin

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009096731A (en) * 2007-10-15 2009-05-07 Kumamoto Univ Carboxymethyl arginine production inhibitor
JP2016006036A (en) * 2014-05-26 2016-01-14 アークレイ株式会社 AGEs-DEGRADING AGENT AND USE THEREOF
JP2018188375A (en) * 2017-04-28 2018-11-29 株式会社アンチエイジングコミュニケーション Pentosidine production inhibitor

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"糖化ストレスと抗糖化作用の評価", オレオサイエンス, vol. 第18巻、第2号, JPN6021033803, 2018, pages 67 - 73, ISSN: 0004584119 *
BIOMED MATER ENG., vol. 25(3), JPN6021022844, 2015, pages 257 - 266, ISSN: 0004528570 *
EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, vol. Volume 2020, Article ID 8321732, JPN6021022845, 19 February 2020 (2020-02-19), pages 1 - 12, ISSN: 0004584118 *
NOTULAE BOTANICAE HORTI AGROBOTANICI CLUJ-NAPOCA, vol. 45(1), JPN6021022847, 2017, pages 179 - 184, ISSN: 0004584117 *
ヘアリプロ史上最多の5種類の有効成分を配合した『へアリプロ 薬用スカルプグロウ JET』4月17日(金)より, JPN6021022846, 17 April 2020 (2020-04-17), ISSN: 0004584116 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023190518A1 (en) * 2022-03-30 2023-10-05 国立研究開発法人産業技術総合研究所 Oxidative stress inhibitor, oxidative stress inhibitory composition, and oxidative stress inhibitory device

Also Published As

Publication number Publication date
KR20210134509A (en) 2021-11-10
CN113577118A (en) 2021-11-02
CN118453674A (en) 2024-08-09
CN113577118B (en) 2024-05-24

Similar Documents

Publication Publication Date Title
KR100958496B1 (en) Composition from natural origin ingridient for hair loss prevention and hair growth effect
JP6697479B2 (en) Composition for promoting hair growth or hair growth and for anti-inflammatory
KR20220091957A (en) Composition for anti-aging, anti-inflammation or skin regeneration containing Cannabis sativa stem extract as effective component
US10617730B2 (en) Composition for preventing alopecia or stimulating hair growth containing extracellular polysaccharide produced from ceriporia lacerata as active ingredient
JP2021175715A (en) Ages formation inhibitory composition
KR101204858B1 (en) Cosmetic Composition for for improving Skin-Wrinkle
JP7134322B2 (en) Composition for suppressing AGEs formation
KR102176710B1 (en) A cosmetic composition comprising fractions of extracts of flower of Forsythia koreana as an active ingredient
CN116240259A (en) Method for extracting compound from ginseng, ginseng extract containing the compound, and composition for enhancing skin barrier containing the same
CN111447937A (en) Synergistic composition as autophagy promoting agent
KR20150105721A (en) Skin-antiaging cosmetical composition containing mixed extract of lycium chinense mill as an active ingredient
KR101441190B1 (en) Cosmetic composition containing Oreocnide fruticosa extraction
JP2021181494A (en) Sebum production inhibitor
KR101688815B1 (en) Composition containing propanoid derivatives for preventing gray hair and for treatment of leukoplakia
KR102610308B1 (en) Composition for promoting hair growth or preventing hair loss comprising Stephanandra incisa extract
KR102491296B1 (en) Skin whitening cosmetic composition using pear peel
JP6047793B2 (en) Enzyme activity inhibitor
EP4385489A1 (en) Hair care composition and banana flower extract and method for hair care using the same
JP7122169B2 (en) Melanin degradation accelerator and whitening cosmetic
US11179319B2 (en) Method for producing cosmetic composition using skin serum
JP5667774B2 (en) Melanin production inhibitor, glutathione production promoter, hyaluronic acid production promoter, involucrin production promoter, and skin cosmetics
KR20090097232A (en) Cosmetic compositions containing extract of viburnum dilatatum thunb used for antiwrinkle
KR20170061802A (en) Composition for skin whitening comprising extract of Castanopsis cuspidata var. sieboldii or Cinnamomum japonicum Siebold
KR20240091664A (en) Cosmetic composition for preventing skin aging comprising extract of citrus unshiu × citrus sinensis as active ingredient
KR20240094190A (en) COMPOSITION FOR PREVENTING, IMPROVING OR TREATING HAIR LOSS CONTAINING Suaeda glauca Bunge EXTRACTS AS AN ACTIVE INGREDIENT AND METHOD FOR PREPARING THE SAME

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210421

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20210421

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210806

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210831